Seeking Alpha

Affymax (AFFY +10.9%) shares resume trading, popping more than 10% after the company confirms...

Affymax (AFFY +10.9%) shares resume trading, popping more than 10% after the company confirms the FDA cleared the company's peginesatide anemia treatment for patients on dialysis for chronic kidney disease. The drug will be AFFY's first marketed product. Competitor Amgen (AMGN +0.5%) also trades higher.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs